🟢 Harrow Health Inc is trading 5.14% up today as VERKAZIA relaunch fuels extended rally

Harrow Health Inc is trading 5.14% up today at $39.59, extending a significant rally that began on June 10.

• The primary catalyst for the move is the relaunch of VERKAZIA, a prescriptive VKC eye treatment, which has revitalized investor optimism surrounding the company's ophthalmology portfolio.
• The stock's recent sequence of strong closes suggests that technical momentum is amplifying the price action beyond the initial impact of the product news.
• While the broader market backdrop remains mildly supportive, no new major company announcements have been released since the prior VERKAZIA-related updates.